DMD and Duchenne muscular dystrophy: Therefore, the precise quantification of dystrophin in muscle tissue is becoming an essential biomarker to monitor the efficiency of these therapies [7], especially since the measurement of dystrophin in individuals with DMD is extremely challenging due to its near-complete absence [8].